- Home
- HPK vs FULC Comparison
HPK vs FULC Comparison
Compare HPK & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HPK | FULC |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.1M | 718.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HPK | FULC |
|---|---|---|
| Price | $6.59 | $7.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $11.00 | ★ $16.38 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.85 | $2.32 |
| 52 Week High | $13.12 | $15.74 |
Technical Indicators
Market Signals| Indicator | HPK | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 33.05 |
| Support Level | $5.14 | $7.40 |
| Resistance Level | $7.33 | $8.17 |
| Average True Range (ATR) | 0.53 | 0.51 |
| MACD | 0.10 | -0.06 |
| Stochastic Oscillator | 86.39 | 9.87 |
Price Performance
Historical ComparisonAbout HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas company focused on the development of unconventional oil and natural gas reserves in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.